Karl Thiel
Investment analyst focused on biotech and Rule Breakers contributor who provides analysis on drug approvals, FDA developments, and sector risk.
Best podcasts with Karl Thiel
Ranked by the Snipd community
12 snips
Feb 2, 2026 • 24min
Biotech Beat NVIDIA in 2025. Can It Do It Again?
Tom King, Rule Breakers analyst who tracks earnings and market trends, and Karl Thiel, biotech-focused analyst who follows drug approvals and FDA shifts. They dig into biotech’s 2025 outperformance versus AI, turmoil and political pressure at the FDA, investment risk and longer timelines for gene and cell therapies, and previews for Lilly, Novo Nordisk, and Twist Bioscience results.
